Scholars@Duke

Endpoint surrogacy in oncology Phase 3 randomised controlled trials.

Publication ,  Journal Article
Zhang, J; Pilar, MR; Wang, X; Liu, J; Pang, H; Brownson, RC; Colditz, GA; Liang, W; He, J
Published in: Br J Cancer
August 2020
Published version (DOI) Open Access Copy (Duke) Link to item

Endpoint surrogacy is an important concept in oncology trials. Using a surrogate endpoint like progression-free survival as the primary endpoint-instead of overall survival-would lead to a potential faster drug approval and therefore more cancer patients with an earlier opportunity to receive the newly approved drugs.

Duke Scholars

Xiaofei Wang
Author Xiaofei Wang Biostatistics & Bioinformatics, Division of Biostatistics
Herbert Pang
Author Herbert Pang Biostatistics & Bioinformatics, Division of Biostatistics

Published In

Br J Cancer

DOI

10.1038/s41416-020-0896-5

EISSN

1532-1827

Publication Date

August 2020

Volume

123

Issue

3

Start / End Page

333 / 334

Location

England

Related Subject Headings

  • Progression-Free Survival
  • Oncology & Carcinogenesis
  • Neoplasms
  • Humans
  • Drug Approval
  • Biomarkers
  • 3211 Oncology and carcinogenesis
  • 1117 Public Health and Health Services
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zhang, J., Pilar, M. R., Wang, X., Liu, J., Pang, H., Brownson, R. C., … He, J. (2020). Endpoint surrogacy in oncology Phase 3 randomised controlled trials. Br J Cancer, 123(3), 333–334. https://doi.org/10.1038/s41416-020-0896-5
Zhang, Jianrong, Meagan R. Pilar, Xiaofei Wang, Jingxia Liu, Herbert Pang, Ross C. Brownson, Graham A. Colditz, Wenhua Liang, and Jianxing He. “Endpoint surrogacy in oncology Phase 3 randomised controlled trials.” Br J Cancer 123, no. 3 (August 2020): 333–34. https://doi.org/10.1038/s41416-020-0896-5.
Zhang J, Pilar MR, Wang X, Liu J, Pang H, Brownson RC, et al. Endpoint surrogacy in oncology Phase 3 randomised controlled trials. Br J Cancer. 2020 Aug;123(3):333–4.
Zhang, Jianrong, et al. “Endpoint surrogacy in oncology Phase 3 randomised controlled trials.” Br J Cancer, vol. 123, no. 3, Aug. 2020, pp. 333–34. Pubmed, doi:10.1038/s41416-020-0896-5.
Zhang J, Pilar MR, Wang X, Liu J, Pang H, Brownson RC, Colditz GA, Liang W, He J. Endpoint surrogacy in oncology Phase 3 randomised controlled trials. Br J Cancer. 2020 Aug;123(3):333–334.

Published In

Br J Cancer

DOI

10.1038/s41416-020-0896-5

EISSN

1532-1827

Publication Date

August 2020

Volume

123

Issue

3

Start / End Page

333 / 334

Location

England

Related Subject Headings

  • Progression-Free Survival
  • Oncology & Carcinogenesis
  • Neoplasms
  • Humans
  • Drug Approval
  • Biomarkers
  • 3211 Oncology and carcinogenesis
  • 1117 Public Health and Health Services
  • 1112 Oncology and Carcinogenesis